FLII and Familial prostate cancer: The AR is known to promote tumor progression in prostate cancer patients, particularly in patients which are no longer responsive to androgen deprivation therapy and suffer aggressive tumors, however, the detrimental effects of AR expression may be overcome by Flii, as overexpression of Flii reduces both tumor size and weight, and reintroduction of Flii to prostate cancer cells can sensitize the cells to chemotherapy drugs bicalutamide and enzalutamide (Wang et al., 2016).